1. Introduction

Clopidogrel bisulfate, a thienopyridine derivative, was approved for the reduction of ischemic events in patients with recent myocardial infarction, stroke, and peripheral arterial disease [1]. It has been introduced into clinical practice for efficient platelet inhibition by inhibiting binding of ADP to its receptor and subsequent ADP-mediated activation of glycoprotein IIb/IIIa complex with fewer side effects than ticlopidine or aspirin [2]. However, there were several reports concerning the potentially fatal types of hematologic dyscrasia associated with clopidogrel therapy, such as aplastic anemia [3], neutropenia [4], pancytopenia [5], thrombocytopenia [6] and thrombocytopenic purpura (TTP)[7]. We experienced a rare but fatal side effect neutropenia after clopidogrel use in a peritoneal dialysis (PD) patient with chronic renal failure who underwent 

percutaneous coronary intervention (PCI).